跳至主要内容
临床试验/NCT05679089
NCT05679089招募中不适用

Assessment of Early Detection Based on Liquid Biopsy in Intracranial Tumors: a Prospective Observational Study

Zhujiang Hospital1 个研究点 分布在 1 个国家目标入组 358 人开始时间: 2022年11月1日最近更新:
适应症

试验速览

阶段
不适用
状态
招募中
发起方
入组人数
358
试验地点
1
主要终点
The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors.

研究概览

简要总结

ASCEND-BRAIN is a prospective, observational study aimed at early-detection of intracranial tumors by combined assays of cfDNA methylation and other biomarkers. The study will enroll approximately 358 participants including intracranial malignant tumors, patients with benign disorders of central nervous system and healthy participants.

研究设计

研究类型
Observational
观察模型
Case Control
时间视角
Prospective

入排标准

年龄范围
40 Years 至 75 Years(Adult, Older Adult)
性别
All
接受健康志愿者

入选标准

  • 未提供

排除标准

  • 未提供

结局指标

主要结局

The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors.

时间窗: 12 months

次要结局

  • The sensitivity and specificity of a cfDNA methylation-based early detection model for intracranial tumors of different grades(WHO I-IV) and mutant subtypes(IDH mutant/wild type).(12 months)

研究者

发起方
Zhujiang Hospital
申办方类型
Other
责任方
Sponsor

研究点 (1)

Loading locations...

相似试验